Full history for every metric is available with a Kvantra account
IBEX Technologies Inc. (IBT.V)
Key financial summary
Financials in CAD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | CAD m | 5 | 4 | 5 | 5 | 8 | 7 | 8 |
| Operating profit | CAD m | -1 | -1 | |||||
| Net profit | CAD m | -0 | -1 | 1 | 1 | 2 | 4 | 4 |
| EPS reported | CAD | 0.16 | 0.16 | |||||
| Operating cashflow per share | CAD | 0.09 | 0.09 | |||||
| Capex per share | CAD | 0.04 | 0.04 | |||||
| FCF per share | CAD | 0.05 | 0.05 | |||||
| Free cash flow | CAD m | 1 | 2 | |||||
| Net debt | CAD m | -7 | -8 | |||||
| Book value equity | CAD m | 14 | 14 | |||||
| Book value per share | CAD | 0.55 | 0.58 | |||||
| Number of shares | m | 24.78 | 24.51 | |||||
| DPS (TTM paid) | CAD | 0.00 | 0.00 |
Financial summary
Financials in CAD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | 7.44 | - | |||||
| P/B LTM | x | 2.17 | 2.50 | |||||
| P/S LTM | x | 3.94 | 4.44 | |||||
| P/FCF LTM | x | 23.78 | 19.99 | |||||
| EV/EBITDA LTM | x | 14.61 | 10.56 | |||||
| EV/Sales LTM | x | 3.01 | 3.39 | |||||
| Earnings Yield LTM | % | 13.44% | 10.84% | |||||
| FCF Yield | % | 4.20% | 5.00% | |||||
| Quality | ||||||||
| ROE | % | 28.61% | 33.34% | |||||
| ROIC | % | -9.71% | -9.71% | |||||
| Operating margin | % | -19.76% | -19.76% | |||||
| Gross margin | % | 69.41% | 69.41% | |||||
| FCF/Sales | % | 16.55% | 16.55% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | +137.39% | +203.61% | |||||
| Sales Growth YoY | % | -5.08% | +3.17% | |||||
| Net Income Growth YoY | % | +132.54% | +187.44% | |||||
| FCF Growth | % | -63.91% | +14.31% | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | 0.76 | 1.13 | |||||
| Net Debt/EBITDA | x | -4.47 | -4.47 | |||||
| EBIT/Net interest | x | -15.13 | -15.13 | |||||
| Net debt/market cap | % | -23.43% | -23.73% | |||||
| Net debt/Equity | x | -0.51 | -0.59 | |||||
| Gross debt/equity | x | 0.12 | 0.11 | |||||
Company overview
Founded in 1972 and based in Montreal, Canada, IBEX Technologies Inc. specializes in the production and global distribution of enzymes tailored for biomedical applications. The company's reach extends to Canada, the United States, Germany, and the United Kingdom, as well as other international markets. Its extensive product catalog features recombinant glycosaminoglycan lyases, such as Heparinase I, II, and III, along with Chondroitinase AC and B. Furthermore, IBEX offers collagen ELISAs designed to investigate the synthesis and breakdown of connective tissue components, complementing these with collagen antibodies and diamine oxidase liquid. They are also a key provider of arthritis assays, essential for research into osteoarthritis. Beyond their product lines, IBEX delivers lyophilization services for disposable medical device parts, in addition to custom fermentation and contract manufacturing capabilities. Their diverse client base encompasses medical device fabricators, quality control facilities, producers of low molecular weight heparin, and academic research institutions.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
IBEX Technologies Inc. (IBT.V)
Founded in 1972 and based in Montreal, Canada, IBEX Technologies Inc. specializes in the production and global distribution of enzymes tailored for biomedical applications. The company's reach extends to Canada, the United States, Germany, and the United Kingdom, as well as other international markets. Its extensive product catalog features recombinant glycosaminoglycan lyases, such as Heparinase I, II, and III, along with Chondroitinase AC and B. Furthermore, IBEX offers collagen ELISAs designed to investigate the synthesis and breakdown of connective tissue components, complementing these with collagen antibodies and diamine oxidase liquid. They are also a key provider of arthritis assays, essential for research into osteoarthritis. Beyond their product lines, IBEX delivers lyophilization services for disposable medical device parts, in addition to custom fermentation and contract manufacturing capabilities. Their diverse client base encompasses medical device fabricators, quality control facilities, producers of low molecular weight heparin, and academic research institutions.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free